ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2025
Investment gaps in antimicrobial resistance research & development: trends in Europe, 2017-2021.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAntimicrobial resistance (AMR) remains one of the world's most pressing health, economic, and social challenges. To combat this crisis, innovative tools have been developed to enhance research and development (R&D) efforts like the Global AMR R&D Hub's Dynamic Dashboard. By aggregating data from projects worldwide, the Dynamic Dashboard highlights trends and gaps in AMR R&D investments, totalling more than 8.22 billion Euros in the period 2017-2021 across the One Health continuum - human, animal, plant and environment. Launched in March 2020, the Dynamic Dashboard supports global priority setting and decision-making in AMR research, fostering strategic planning to promote efficient use of international resources and cross sectoral collaboration in AMR R&D.
methodsRecognizing the urgent need for innovative diagnostics, treatments, and prevention strategies against AMR, here we presented a comprehensive analysis of public and philanthropic investments in AMR R&D obtained from January 2017 to December 2021 across Europe.
resultsWe calculated the investments by One Health sector, year of funding, gross domestic product (GDP), research area, type of project, and infectious agent to raise awareness and promote global visibility of the R&D landscape in Europe. Our analysis revealed limited AMR R&D investments in the non-human sectors and non-bacterial topics, geographical polarization of funders, and some unaligned trends between the amount of investments and number of projects funded over the study period. DISCUSSION: Harnessing these data-driven insights, we aimed to inform stakeholders and optimize the allocation of economic resources for AMR R&D. Prioritizing unmet needs with the greatest potential for impact in this field will expedite the development of effective solutions to mitigate the global threat of AMR.
Indexed as
Identifiers
40419730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.